The results of an allergen POC trial in asthmatics will summarized by Dr. David Ramos, principal investigator of the PBF-680 clinical program, in an oral presentation titled: PBF-680, an oral A1 adenosine...

The results confirm a clinically and statistically significant improvement in trough FEV1 of asthmatic patients taking 10mg of PBF-680 for 14 days compared to placebo. Additionally, patients administered...

The company announced the initiation a of a drug discovery program towards the identification of novel oral drugs specifically designed to treat infections caused by Corona viruses. Recent scientific...

Includes royalty interest in NIR178  September 30 2019 XOMA Corporation (NASDAQ: XOMA), announced today it has acquired a royalty interest in six clinical-stage assets targeting the adenosine pathway for...